...
search icon
apm-img

Aptorum Group Ltd Class A, Common Stock

APM

NAQ

$1.07

-$0.06

(-5.29%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$7.14M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
21.34K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.46 L
$5.05 H
$1.07

About Aptorum Group Ltd Class A, Common Stock

Aptorum Group Limited, through its subsidiaries, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products to treat oncology and infectious diseases. Its pipeline products include SACT-1, a repurposed drug candidate, which is in phase 1 clinical trial to treat neuroblastoma and other cancer types; ALS-4, a repurposed small molecule, which is in phase 1 clinical trial for the treatment of bacterial infections, such as staphylococcus aureus, mycobacterium tuberculosis, and pseudomonas aeruginosa; and RPIDD, a liquid biopsy rapid pathogen diagnostic which is in preclinical trial to treat pathogen molecular diagnostics. The company also develops SACT-COV19, a repurposed small molecule which is in preclinical trial for the treatment of coronavirus disease; SACT-2 and SACT-3; ALS-1, a small molecule which is in preclinical trial to treat bacterial infections caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus (MRSA); and ALS-2/3, a small molecule which is in preclinical trial for the treatment of gram+ve bacterial infections. In addition, it is developing NLS-1, which is in preclinical trial for the treatment of endometriosis; DLS-1+2, which is in preclinical trial to treat NSCLC with mutation; DLS-3, which is in preclinical trial to treat autoimmune disease; CLS-1, a macromolecule, which is in preclinical trial to treat obesity; and CLS-1 and CLS-3. Further, the company offers NativusWell DOI (NLS-2), a dietary supplement for women undergoing menopause; and provides management services. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAPMSectorS&P500
1-Week Return3.38%0.84%0.59%
1-Month Return15.2%-1.33%2.86%
3-Month Return18.9%-9.16%6.93%
6-Month Return42.15%-6.9%-0.56%
1-Year Return-76.22%-8.72%11.95%
3-Year Return-91.18%6.9%53.86%
5-Year Return-97.45%30.65%88%
10-Year Return-99.25%79.2%185.13%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue911.51K1.54M1.30M431.38K-[{"date":"2020-12-31","value":59.12,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.05,"profit":true},{"date":"2023-12-31","value":27.98,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue1.02M1.46M1.22M420.81K-[{"date":"2020-12-31","value":69.53,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":83.28,"profit":true},{"date":"2023-12-31","value":28.82,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(103.51K)81.85K80.06K10.57K-[{"date":"2020-12-31","value":-126.46,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.81,"profit":true},{"date":"2023-12-31","value":12.91,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(11.36%)5.31%6.18%2.45%-[{"date":"2020-12-31","value":-183.81,"profit":false},{"date":"2021-12-31","value":85.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":39.64,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses20.17M19.29M17.59M10.73M3.00M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.62,"profit":true},{"date":"2022-12-31","value":87.2,"profit":true},{"date":"2023-12-31","value":53.22,"profit":true},{"date":"2024-12-31","value":14.88,"profit":true}]
Operating Income(19.88M)(19.06M)(22.96M)(10.72M)(3.00M)[{"date":"2020-12-31","value":-1987873000,"profit":false},{"date":"2021-12-31","value":-1906108800,"profit":false},{"date":"2022-12-31","value":-2296303000,"profit":false},{"date":"2023-12-31","value":-1072425100,"profit":false},{"date":"2024-12-31","value":-300229800,"profit":false}]
Total Non-Operating Income/Expense24.95M(8.00M)6.21M6.26M(1.16M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-32.06,"profit":false},{"date":"2022-12-31","value":24.89,"profit":true},{"date":"2023-12-31","value":25.1,"profit":true},{"date":"2024-12-31","value":-4.63,"profit":false}]
Pre-Tax Income4.92M(27.11M)(11.53M)(4.34M)(4.16M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-551.08,"profit":false},{"date":"2022-12-31","value":-234.24,"profit":false},{"date":"2023-12-31","value":-88.23,"profit":false},{"date":"2024-12-31","value":-84.5,"profit":false}]
Income Taxes(1.51M)(1.83M)(6.21M)(1.52M)-[{"date":"2020-12-31","value":-150624800,"profit":false},{"date":"2021-12-31","value":-182595600,"profit":false},{"date":"2022-12-31","value":-621066400,"profit":false},{"date":"2023-12-31","value":-151633200,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes6.43M(25.29M)(5.31M)(2.82M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-393.51,"profit":false},{"date":"2022-12-31","value":-82.7,"profit":false},{"date":"2023-12-31","value":-43.95,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations4.92M(27.11M)(11.53M)(4.34M)(4.16M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-551.08,"profit":false},{"date":"2022-12-31","value":-234.24,"profit":false},{"date":"2023-12-31","value":-88.23,"profit":false},{"date":"2024-12-31","value":-84.5,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income7.07M(25.29M)(5.31M)(2.82M)(4.27M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-357.84,"profit":false},{"date":"2022-12-31","value":-75.2,"profit":false},{"date":"2023-12-31","value":-39.97,"profit":false},{"date":"2024-12-31","value":-60.39,"profit":false}]
EPS (Diluted)(0.59)----[{"date":"2020-12-31","value":-58.57,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

APM
Current Ratio 0.22

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

APM
ROA (LTM) -8.33%
ROE (LTM) -30.62%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

APM
Debt Ratio Lower is generally better. Negative is bad. 0.27
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 1.31

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

APM
Trailing PE NM
Forward PE NM
P/S (TTM) 23.35
P/B 0.38
Price/FCF NM
EV/R 31.22
EV/Ebitda NM

FAQs

What is Aptorum Group Ltd Class A share price today?

Aptorum Group Ltd Class A (APM) share price today is $1.07

Can Indians buy Aptorum Group Ltd Class A shares?

Yes, Indians can buy shares of Aptorum Group Ltd Class A (APM) on Vested. To buy Aptorum Group Ltd Class A from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aptorum Group Ltd Class A be purchased?

Yes, you can purchase fractional shares of Aptorum Group Ltd Class A (APM) via the Vested app. You can start investing in Aptorum Group Ltd Class A (APM) with a minimum investment of $1.

How to invest in Aptorum Group Ltd Class A shares from India?

You can invest in shares of Aptorum Group Ltd Class A (APM) via Vested in three simple steps:

  • Click on Sign Up or Invest in APM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aptorum Group Ltd Class A shares
What is Aptorum Group Ltd Class A 52-week high and low stock price?

The 52-week high price of Aptorum Group Ltd Class A (APM) is $5.05. The 52-week low price of Aptorum Group Ltd Class A (APM) is $0.46.

What is Aptorum Group Ltd Class A price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aptorum Group Ltd Class A (APM) is 0.38

What is the Market Cap of Aptorum Group Ltd Class A?

The market capitalization of Aptorum Group Ltd Class A (APM) is $7.14M

What is Aptorum Group Ltd Class A’s stock symbol?

The stock symbol (or ticker) of Aptorum Group Ltd Class A is APM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top